Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer

Wei Ching Chen, Yung Sheng Chang, Hui Ping Hsu, Meng Chi Yen, Hau Lun Huang, Chien Yu Cho, Chih Yang Wang, Tzu Yang Weng, Po Ting Lai, Ching Shih Chen, Yih Jyh Lin, Ming Derg Lai

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

CD90 is used as a marker for cancer stem cell in liver cancer. We aimed to study the mechanism by which CD90 promoted liver cancer progression and identify the new therapeutic targets on CD90 signal pathway. Ectopic expression of CD90 in liver cancer cell lines enhanced anchorage-independent growth and tumor progression. Furthermore, CD90 promoted sphere formation in vitro and upregulated the expression of the cancer stem cell marker CD133. The CD133 expression was higher in CD45-CD90+ cells in liver cancer specimen. The natural carcinogenic molecules TGF-β-1, HGF, and hepatitis B surface antigen increased the expression of CD90 and CD133. Inhibition of CD90 by either shRNA or antibody attenuated the induction of CD133 and anchorage-independent growth. Lentiviral delivery of CD133 shRNA abolished the tumorigenicity induced by CD90. Ectopic expression of CD90 induced mTOR phosphorylation and AMPK dephosphorylation. Mutation of integrin binding-RLD domain in CD90 attenuated the induction of CD133 and anchorage-independent growth. Similar results were observed after silencing β3 integrin. Signaling analyses revealed that AMPK/mTOR and β3 integrin were required for the induction of CD133 and tumor formation by CD90. Importantly, the energy restriction mimetic agent OSU-CG5 reduced the CD90 population in fresh liver tumor sample and repressed the tumor growth. In contrast, sorafenib did not decrease the CD90+ population. In conclusion, the signal axis of CD90-integrin-mTOR/AMPK-CD133 is critical for promoting liver carcinogenesis. Molecules inhibiting the signal axis, including OSU-CG5 and other inhibitors, may serve as potential novel cancer therapeutic targets in liver cancer.

Original languageEnglish
Pages (from-to)42923-42937
Number of pages15
JournalOncotarget
Volume6
Issue number40
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

AMP-Activated Protein Kinases
Liver Neoplasms
Integrins
Neoplastic Stem Cells
Neoplasms
Growth
Small Interfering RNA
Therapeutics
Liver
Population Dynamics
Hepatitis B Surface Antigens
Signal Transduction
Carcinogenesis
Phosphorylation
Cell Line
Mutation
Antibodies
Population

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Chen, Wei Ching ; Chang, Yung Sheng ; Hsu, Hui Ping ; Yen, Meng Chi ; Huang, Hau Lun ; Cho, Chien Yu ; Wang, Chih Yang ; Weng, Tzu Yang ; Lai, Po Ting ; Chen, Ching Shih ; Lin, Yih Jyh ; Lai, Ming Derg. / Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer. In: Oncotarget. 2015 ; Vol. 6, No. 40. pp. 42923-42937.
@article{d35b532dbed74c57a7c8421eccde47c2,
title = "Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer",
abstract = "CD90 is used as a marker for cancer stem cell in liver cancer. We aimed to study the mechanism by which CD90 promoted liver cancer progression and identify the new therapeutic targets on CD90 signal pathway. Ectopic expression of CD90 in liver cancer cell lines enhanced anchorage-independent growth and tumor progression. Furthermore, CD90 promoted sphere formation in vitro and upregulated the expression of the cancer stem cell marker CD133. The CD133 expression was higher in CD45-CD90+ cells in liver cancer specimen. The natural carcinogenic molecules TGF-β-1, HGF, and hepatitis B surface antigen increased the expression of CD90 and CD133. Inhibition of CD90 by either shRNA or antibody attenuated the induction of CD133 and anchorage-independent growth. Lentiviral delivery of CD133 shRNA abolished the tumorigenicity induced by CD90. Ectopic expression of CD90 induced mTOR phosphorylation and AMPK dephosphorylation. Mutation of integrin binding-RLD domain in CD90 attenuated the induction of CD133 and anchorage-independent growth. Similar results were observed after silencing β3 integrin. Signaling analyses revealed that AMPK/mTOR and β3 integrin were required for the induction of CD133 and tumor formation by CD90. Importantly, the energy restriction mimetic agent OSU-CG5 reduced the CD90 population in fresh liver tumor sample and repressed the tumor growth. In contrast, sorafenib did not decrease the CD90+ population. In conclusion, the signal axis of CD90-integrin-mTOR/AMPK-CD133 is critical for promoting liver carcinogenesis. Molecules inhibiting the signal axis, including OSU-CG5 and other inhibitors, may serve as potential novel cancer therapeutic targets in liver cancer.",
author = "Chen, {Wei Ching} and Chang, {Yung Sheng} and Hsu, {Hui Ping} and Yen, {Meng Chi} and Huang, {Hau Lun} and Cho, {Chien Yu} and Wang, {Chih Yang} and Weng, {Tzu Yang} and Lai, {Po Ting} and Chen, {Ching Shih} and Lin, {Yih Jyh} and Lai, {Ming Derg}",
year = "2015",
month = "1",
day = "1",
doi = "10.18632/oncotarget.5976",
language = "English",
volume = "6",
pages = "42923--42937",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "40",

}

Chen, WC, Chang, YS, Hsu, HP, Yen, MC, Huang, HL, Cho, CY, Wang, CY, Weng, TY, Lai, PT, Chen, CS, Lin, YJ & Lai, MD 2015, 'Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer', Oncotarget, vol. 6, no. 40, pp. 42923-42937. https://doi.org/10.18632/oncotarget.5976

Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer. / Chen, Wei Ching; Chang, Yung Sheng; Hsu, Hui Ping; Yen, Meng Chi; Huang, Hau Lun; Cho, Chien Yu; Wang, Chih Yang; Weng, Tzu Yang; Lai, Po Ting; Chen, Ching Shih; Lin, Yih Jyh; Lai, Ming Derg.

In: Oncotarget, Vol. 6, No. 40, 01.01.2015, p. 42923-42937.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer

AU - Chen, Wei Ching

AU - Chang, Yung Sheng

AU - Hsu, Hui Ping

AU - Yen, Meng Chi

AU - Huang, Hau Lun

AU - Cho, Chien Yu

AU - Wang, Chih Yang

AU - Weng, Tzu Yang

AU - Lai, Po Ting

AU - Chen, Ching Shih

AU - Lin, Yih Jyh

AU - Lai, Ming Derg

PY - 2015/1/1

Y1 - 2015/1/1

N2 - CD90 is used as a marker for cancer stem cell in liver cancer. We aimed to study the mechanism by which CD90 promoted liver cancer progression and identify the new therapeutic targets on CD90 signal pathway. Ectopic expression of CD90 in liver cancer cell lines enhanced anchorage-independent growth and tumor progression. Furthermore, CD90 promoted sphere formation in vitro and upregulated the expression of the cancer stem cell marker CD133. The CD133 expression was higher in CD45-CD90+ cells in liver cancer specimen. The natural carcinogenic molecules TGF-β-1, HGF, and hepatitis B surface antigen increased the expression of CD90 and CD133. Inhibition of CD90 by either shRNA or antibody attenuated the induction of CD133 and anchorage-independent growth. Lentiviral delivery of CD133 shRNA abolished the tumorigenicity induced by CD90. Ectopic expression of CD90 induced mTOR phosphorylation and AMPK dephosphorylation. Mutation of integrin binding-RLD domain in CD90 attenuated the induction of CD133 and anchorage-independent growth. Similar results were observed after silencing β3 integrin. Signaling analyses revealed that AMPK/mTOR and β3 integrin were required for the induction of CD133 and tumor formation by CD90. Importantly, the energy restriction mimetic agent OSU-CG5 reduced the CD90 population in fresh liver tumor sample and repressed the tumor growth. In contrast, sorafenib did not decrease the CD90+ population. In conclusion, the signal axis of CD90-integrin-mTOR/AMPK-CD133 is critical for promoting liver carcinogenesis. Molecules inhibiting the signal axis, including OSU-CG5 and other inhibitors, may serve as potential novel cancer therapeutic targets in liver cancer.

AB - CD90 is used as a marker for cancer stem cell in liver cancer. We aimed to study the mechanism by which CD90 promoted liver cancer progression and identify the new therapeutic targets on CD90 signal pathway. Ectopic expression of CD90 in liver cancer cell lines enhanced anchorage-independent growth and tumor progression. Furthermore, CD90 promoted sphere formation in vitro and upregulated the expression of the cancer stem cell marker CD133. The CD133 expression was higher in CD45-CD90+ cells in liver cancer specimen. The natural carcinogenic molecules TGF-β-1, HGF, and hepatitis B surface antigen increased the expression of CD90 and CD133. Inhibition of CD90 by either shRNA or antibody attenuated the induction of CD133 and anchorage-independent growth. Lentiviral delivery of CD133 shRNA abolished the tumorigenicity induced by CD90. Ectopic expression of CD90 induced mTOR phosphorylation and AMPK dephosphorylation. Mutation of integrin binding-RLD domain in CD90 attenuated the induction of CD133 and anchorage-independent growth. Similar results were observed after silencing β3 integrin. Signaling analyses revealed that AMPK/mTOR and β3 integrin were required for the induction of CD133 and tumor formation by CD90. Importantly, the energy restriction mimetic agent OSU-CG5 reduced the CD90 population in fresh liver tumor sample and repressed the tumor growth. In contrast, sorafenib did not decrease the CD90+ population. In conclusion, the signal axis of CD90-integrin-mTOR/AMPK-CD133 is critical for promoting liver carcinogenesis. Molecules inhibiting the signal axis, including OSU-CG5 and other inhibitors, may serve as potential novel cancer therapeutic targets in liver cancer.

UR - http://www.scopus.com/inward/record.url?scp=84952360519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952360519&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.5976

DO - 10.18632/oncotarget.5976

M3 - Article

C2 - 26556861

AN - SCOPUS:84952360519

VL - 6

SP - 42923

EP - 42937

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 40

ER -